Guerreiro Cátia Sá, Hartz Zulmira, Sambo Luís, Conceição Cláudia, Dussault Gilles, Russo Giuliano, Viveiros Miguel, Silveira Henrique, Pita Barros Pedro, Ferrinho Paulo
R&D Unit. Instituto de Higiene e Medicina Tropical. Universidade Nova de Lisboa. Lisboa. Portugal.
Nova School of Business and Economics. Universidade Nova de Lisboa. Lisboa. Portugal.
Acta Med Port. 2017 Feb 27;30(2):141-147. doi: 10.20344/amp.8011.
The global debate on scientific research policy for human health has been led by World Health Organisation with important contributions from other stakeholders such as Council on Health Research for Development, the World Bank and the Global Forum for Health Research. Recently it has been dominated by the thematic agendas of major global financiers. There is a growing interest worldwide in making better use of the evidence resulting from scientific research in health, in the decision-making process regarding health policies, which is fraught with difficulties, as it is the case in Europe. After more than 40 years of democracy and 30 years of European integration, Portugal has bridged the research gap it had previously. However, when compared to global and European research policies, Portugal still has a long way to go regarding investment in research and development.
关于人类健康科学研究政策的全球辩论由世界卫生组织主导，其他利益相关者也做出了重要贡献，如卫生研究促进发展理事会、世界银行和全球卫生研究论坛。最近，它一直由主要全球资助者的主题议程主导。在卫生政策决策过程中更好地利用卫生科学研究产生的证据，这在全球范围内的兴趣日益浓厚，而这一过程充满困难，欧洲也是如此。经过40多年的民主和30年的欧洲一体化，葡萄牙弥补了此前存在的研究差距。然而，与全球和欧洲的研究政策相比，葡萄牙在研发投资方面仍有很长的路要走。
